A Phase II Clinical Trial of Intermittent Letrozole Therapy in Postmenopausal Women With CA 15-3 Positive (Carcinoma Antigen 15-3), Hormone Receptor Positive, Metastatic Breast Cancer
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Letrozole (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Mar 2017 Status changed from completed to discontinued.
- 06 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2013 Planned end date changed from 1 Oct 2012 to 1 Mar 2014 as reported by ClinicalTrials.gov.